This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Feng, W.-h. Articles by Kenney, S. C. Search for Related Content PubMed PubMed Citation Articles by Feng, W.-h. Articles by Kenney, S. C.

Valproic Acid Enhances the Efficacy of Chemotherapy in EBV-Positive Tumors by Increasing Lytic Viral Gene Expression

¹ Departments of Medicine and Microbiology and Immunology and Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina and ² Departments of Medicine and Medical Microbiology, University of Wisconsin at Madison, Madison, Wisconsin

Requests for reprints: Shannon C. Kenney, 421A McArdle, 1400 University Avenue, University of Wisconsin at Madison, Madison, WI 53706. Phone: 608-265-0533; E-mail: skenney{at}wisc.edu.

EBV infection in tumor cells is generally restricted to the latent forms of viral infection. Switching the latent form of viral infection into the lytic form may induce tumor cell death. We have previously reported that certain chemotherapy agents can increase the amount of lytic viral gene expression in EBV-positive tumor cells. In this report, we have explored the potential utility of valproic acid (VPA), an anti-seizure drug that also has strong histone deacetylase inhibitory activity, for activating lytic viral gene expression in EBV-positive tumors. Although VPA treatment alone induced only a modest increase in the level of lytic viral gene expression, it strongly enhanced the ability of chemotherapeutic agents to induce lytic EBV gene expression in EBV-positive epithelial and lymphoid cells in vitro. Furthermore, VPA enhanced cell killing in vitro by chemotherapeutic agents in lymphoblastoid cells and gastric cells (AGS) containing wild-type EBV. In contrast, VPA did not enhance the cytotoxicity of chemotherapy in lymphoblastoid cells containing a lytic-defective (BZLF1-knockout) form of EBV or in EBV-negative AGS cells. Finally, we found that the combination of VPA and chemotherapy was significantly more effective in inhibiting EBV-driven lymphoproliferative disease in severe combined immunodeficient mice than chemotherapy alone. These results suggest that VPA could potentiate the efficacy of chemotherapy for EBV-positive tumors in patients. (Cancer Res 2006; 66(17): 8762-9)

This article has been cited by other articles:

				J. Countryman, L. Gradoville, S. Bhaduri-McIntosh, J. Ye, L. Heston, S. Himmelfarb, D. Shedd, and G. Miller Stimulus Duration and Response Time Independently Influence the Kinetics of Lytic Cycle Reactivation of Epstein-Barr Virus J. Virol., October 15, 2009; 83(20): 10694 - 10709. [Abstract] [Full Text] [PDF]

				J. I. Cohen, H. Kimura, S. Nakamura, Y.-H. Ko, and E. S. Jaffe Epstein-Barr virus-associated lymphoproliferative disease in non-immunocompromised hosts: a status report and summary of an international meeting, 8-9 September 2008 Ann. Onc., September 1, 2009; 20(9): 1472 - 1482. [Abstract] [Full Text] [PDF]

				J. Kawada, P. Zou, R. Mazitschek, J. E. Bradner, and J. I. Cohen Tubacin Kills Epstein-Barr Virus (EBV)-Burkitt Lymphoma Cells by Inducing Reactive Oxygen Species and EBV Lymphoblastoid Cells by Inducing Apoptosis J. Biol. Chem., June 19, 2009; 284(25): 17102 - 17109. [Abstract] [Full Text] [PDF]

				J. Zhou, A. R. Snyder, and P. M. Lieberman Epstein-Barr Virus Episome Stability Is Coupled to a Delay in Replication Timing J. Virol., March 1, 2009; 83(5): 2154 - 2162. [Abstract] [Full Text] [PDF]

				J. K. Countryman, L. Gradoville, and G. Miller Histone Hyperacetylation Occurs on Promoters of Lytic Cycle Regulatory Genes in Epstein-Barr Virus-Infected Cell Lines Which Are Refractory to Disruption of Latency by Histone Deacetylase Inhibitors J. Virol., May 15, 2008; 82(10): 4706 - 4719. [Abstract] [Full Text] [PDF]

				H.-H. Lee, S.-S. Chang, S.-J. Lin, H.-H. Chua, T.-J. Tsai, K. Tsai, Y.-C. Lo, H.-C. Chen, and C.-H. Tsai Essential role of PKC{delta} in histone deacetylase inhibitor-induced Epstein-Barr virus reactivation in nasopharyngeal carcinoma cells J. Gen. Virol., April 1, 2008; 89(4): 878 - 883. [Abstract] [Full Text] [PDF]

				M. Michaelis, T. A. T. Ha, H. W. Doerr, and J. Cinatl Jr Valproic acid interferes with antiviral treatment in human cytomegalovirus-infected endothelial cells Cardiovasc Res, February 1, 2008; 77(3): 544 - 550. [Abstract] [Full Text] [PDF]

				W.-h. Feng, R. J. Kraus, S. J. Dickerson, H. J. Lim, R. J. Jones, X. Yu, J. E. Mertz, and S. C. Kenney ZEB1 and c-Jun Levels Contribute to the Establishment of Highly Lytic Epstein-Barr Virus Infection in Gastric AGS Cells J. Virol., September 15, 2007; 81(18): 10113 - 10122. [Abstract] [Full Text] [PDF]